Vaccines for the 21st Century: A Tool for Decisionmaking

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

Free PDF Access

Sign in to download PDF book and chapters

Free Resources

Related Titles

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "Appendix 5: Enterotoxigenic E. coli." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

Page
175


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Vaccines for the 21st Century: A Tool for Decisionmaking

Table A5–1 Health Care Costs Associated with ETEC Disease

	% of Cases	Duration (years)	% with Care	Cost per Case	Cost per Unit	Units per Case	Form of Treatment
Mile-moderate illness	90%
Diarrhea		0.0110	100%	$10	$10	1.0	Medication A
		0.0110	15%	$50	$50	1.0	Physician A
		0.0110	15%	$10	$10	1.0	Other costs (diapers/oral rehydration therapy)
Prolonged illness	10%
Acute manifestations		0.0219	100%	$10	$10	1.0	Medication A
		0.0219	15%	$50	$50	1.0	Physician A
		0.0219	15%	$20	$10	2.0	Other costs (diapers/oral rehydration therapy)

Page
175

Front Matter (R1-R12)

Executive Summary (1-10)

Introduction (11-16)

Progress in Vaccine Development (17-38)

Considerations of Candidate Vaccines (39-52)

Overview of Analytic Approach and Results (53-92)

Review of the Analytical Model (93-108)

Ethical Considerations and Caveats (109-122)

Observations (123-132)

References (133-142)

Appendix 1: Borrelia burgdorferi (143-148)

Appendix 2: Chlamydia (149-158)

Appendix 3: Coccidioides Immitis (159-164)

Appendix 4: Cytomegalovirus (165-172)

Appendix 5: Enterotoxigenic E. coli (173-176)

Appendix 6: Epstein-Barr Virus (177-180)

Appendix 7: Helicobacter pylori (181-188)

Appendix 8: Hepatitis C (189-194)

Appendix 9: Herpes Simplex Virus (195-206)

Appendix 10: Histoplasma capsulatum (207-212)

Appendix 11: Human Paillomavirus (213-222)

Appendix 12: Influenza A and B (223-232)

Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)

Appendix 14: Melanoma (239-244)

Appendix 15: Multiple Sclerosis (245-250)

Appendix 16: Mycobacterium tuberculosis (251-256)

Appendix 17: Neisseria gonnorrhea (257-266)

Appendix 18: Neisseria meningitidis (267-272)

Appendix 19: Parainfluenza Virus (273-278)

Appendix 20: Respiratory Syncytial Virus (279-284)

Appendix 21: Rheumatoid Arthritis (285-290)

Appendix 22: Rotavirus (291-294)

Appendix 23: Shigella (295-298)

Appendix 24: Streptococcus, Group A (299-304)

Appendix 25: Streptococcus, Group B (305-312)

Appendix 26: Streptococcus pneumoniae (313-322)

Appendix 27: Information on accessing Electronic Spreadsheets (323-324)

Appendix 28: Summary of Workshops (325-434)

Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)

Index (443-460)